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ABSTRACT 
Gemcitabine Hydrochloride is a BCS class III drug of choice in the treatment of cancer, as a single or in combination chemotherapy. 
However, its bioavailability is a major concern due to its short half-life. Solid lipid nanoparticles (SLN) of Gemcitabine 
Hydrochloride were prepared to enhance its bioavailability, hence anticancer activity. The Quality by Design approach was applied 
for the formulation of SLN. The Randomized 32 factorial design was used with responses of particle size and % entrapment 
efficiency (% EE). The optimized batch of Gemcitabine Hydrochloride loaded SLN containing 1gm of GMS as solid lipid, 1gm of 
Tween80: Sodium Taurocholate as surfactant: co-surfactant and 5mg of Gemcitabine Hydrochloride was prepared by high shear 
homogenization method followed by Probe sonication for 15min to form nanoparticulate SLN dispersion. The Optimized batch of 
Gemcitabine Hydrochloride loaded SLN that exhausted mean particle size of 126.1nm, zeta potential -28.6 mV and % EE 74.83% 
respectively. SEM studies revealed three-dimensional nature of SLN with a slightly rough surface. DSC, results exhibited 
entrapment of Gemcitabine Hydrochloride in SLN. The optimized batch of SLN was evaluated for in-vitro % drug release using 
cellulose membrane dialysis bags for 24hrs and showed 63.13% CDR at 24 hrs. Anticancer cell line studies were also performed in 
human lung cancer cell line (A-549). It concludes that Gemcitabine Hydrochloride loaded Solid lipid Nanoparticles was successfully 
formulated and evaluated to sustain the drug release by bypassing the first pass metabolism. 
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INTRODUCTION: 
Numerous psychological and pathological factors concur 
in the gradual advancement of the disease, thus 
progressing in many cases to death. Even though death 
represents an extreme outcome in the pathology, food 
contaminants, besides environmental and chemical 
factors contribute to the development of new cases of 
cancer each year and an ever-increasing number of 
patients are necessarily subjected to therapeutic 
protocols. For this reason, researchers have been 
focusing their attention on the investigation of novel 
innovative drug delivery of anti-cancer drug, in order to 
improve the quality of standard chemotherapy. 
Gemcitabine (2’.2’ difluoro deoxycytidine) is a 
fluorinated nucleoside analog of cytosine arabinoside 
(Ara-C) known for potential antitumor effects and 
radiation sensitization
1-2
. Mainly it is used as a drug of 
choice for various cancers such as pancreatic, non-small 
cell lung, ovarian, bladder, neck and head etc. 
Gemcitabine Hydrochloride exerts its activity through 
the inhibition of DNA synthesis by chain termination 
method. Being a potent antitumor agent, Gemcitabine 
Hydrochloride is not able to maintain an optimum 
concentration in the body, because of its very short half-
life (short infusions 32 to 94 minutes, long infusions 245 
to 638 minutes) and highly hydrophilic nature
3-4
. After 
systemic administration in the body, Gemcitabine 
hydrochloride is rapidly inactivated to a metabolite 2’-
deoxy- 2’, 2’difluoro uridine by cytidine deaminase. The 
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major limitations of gemcitabine Hydrochloride is short 
half-life and strong side effects when administered 
intravenously. Short half lives are commonly due to fast 
renal clearance, decreased protein binding and 
enzymatic degradation. Inherent drawbacks of parenteral 
Gemcitabine Hydrochloride administration warrant an 
alternative drug delivery system
5
. Solid Lipid 
Nanoparticles offer great promise to improve therapeutic 
effectiveness and safety profile of the conventional form 
of cancer chemotherapy. Hence in the present work, an 
attempt is being made to provide an alternative colloidal 
drug delivery system for gemcitabine hydrochloride in 
the form of Solid lipid nanoparticles. Quality by Design 
is the modern approach for quality of pharmaceuticals. 
The aim of pharmaceutical development is to design a 
quality product and its manufacturing process to 
consistency deliver the intended performance of the 
product. The information and knowledge gained from 
pharmaceutical development studies and manufacturing 
experience provide scientific understanding to support 
the establishment of the design space, specification, and 
manufacturing controls.  
MATERIALS AND METHOD: 
Materials: 
Gemcitabine Hydrochloride was obtained as a gift 
sample from Renuka Raw Pharma (Mumbai), India. All 
over chemicals were purchased from Merck Research 
Lab., Fine Chem Industries, Mumbai, India. 
Methods: 
Preformulation Studies: 
The drug substance of Gemcitabine Hydrochloride and 
excipients were characterized for their identity and 
purity. The following studies were performed: 
Determination of λmax of Gemcitabine Hydrochloride 
in PBS (PH 7.4):  
Standard stock solution containing Gemcitabine 
Hydrochloride was prepared by dissolving 10 mg of 
Gemcitabine Hydrochloride in 100 ml Phosphate Buffer 
pH 7.4 in volumetric flask. A solution containing 10 
µg/ml of Gemcitabine Hydrochloride was scanned in the 
range of 200 – 400 nm.  
Compatibility Studies 
Compatibility of the Gemcitabine Hydrochloride with 
lipids used to formulate SLN was established by FTIR 
spectral analysis. FTIR Spectral analysis of Gemcitabine 
Hydrochloride, individual lipids and combination of 
Gemcitabine Hydrochloride and lipids was carried out to 
investigate the changes in chemical composition of the 
drug after combining it with the excipients. 
Compatibility study was carried out on Fourier 
Transform Infrared spectrometer. 
Design of Experiment by Quality by Design (QBD) 
Quality by design (QBD) principles was applied to gain 
an understanding of formulation of SLN. The following 
attributes were identified: 
Quality Target Product Profile (QTPP) for the Solid 
Lipid Nanoparticles 
As per the ICH guidelines Q8 QTTP were defined on the 
basis of properties of drug substance
10
. Following QTTP 
parameters of Gemcitabine Hydrochloride loaded SLN 
were considered to be important as described in Table 
No. 1.  
 
Table 1: Quality Target Product Profile (QTPP) for SLN 
QTPP Elements Target Justification 
Dosage Form Freeze dried SLN SR product required SLN dosage form 
Dosage design Sustained Release SLN Give better effect and acceptable to patient 
Route of Administration Parenteral  Most preferred route of administration for this drug 
 
Critical Quality Attributes (CQA) 
Table No. 2 summarizes the quality attributes of SLN and indicates which attribute were classified as drug product 
critical quality attributes (CQAs)
10
. 
Table 2: Critical Quality Attributes (CQA) of SLN 
Quality Attributes of the 
Drug Product 
Target Is this a 
CQA? 
Justification 
Physical 
Attributes 
Appearance Color should be acceptable, 
odour and taste should be 
masked 
No Color, odor and appearance are not directly 
linked to safety and efficacy. Therefore they 
are not critical. 
Size Size of the SLN should be 
in Nanometer range 
Yes Small size of the SLN is responsible for its 
prolonged release of action. Therefore it 
was considered as CQA. 
% Entrapment Efficiency 70-90% Yes %EE is critical while adjusting the dose of 
the formulation 
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Risk Assessment: 
A risk assessment of the drug substance attributes was 
performed to evaluate the impact of each attribute could 
have on the drug product CQAs. The relative risk that 
each attribute presents was ranked as high, medium or 
low. 
Initial Risk Assessment Related to Formulation 
Development: 
 
Table 3: Initial Risk Assessment of Formulation Variables 
Drug Product CQAs 
Formulation Variables 
Concentration of GMS 
Concentration of Tween 80: 
Sodium Taurocholate 
Sonication Time 
Particle Size of SLN High  High  High 
%EE Low  Low  Low  
 
Table 4: Justification for the Initial Risk Assessment of Formulation Variables 
Formulation Variables Drug Product CQAs Justification 
Concentration of GMS 
Particle Size  
As the concentration of lipid increases particle size of SLN 
increases, hence risk was high. 
% EE 
Increase in the concentration of lipid doesn’t affect the 
%EE, hence risk was low. 
Concentration of Tween 80: 
Sodium Taurocholate 
Particle Size  
As the concentration of surfactant increases particle size of 
SLN decreases, hence risk was High. 
% EE 
As the concentration of surfactant increases %EE of SLN 
increases, hence risk was low. 
 
Initial Risk Assessment of Drug Product 
Manufacturing Process: 
Risk assessment of the overall drug product 
manufacturing process was performed to identify the 
high risk steps that may affect CQAs of final drug 
product. These variables were then investigated in order 
to better understand the manufacturing process and to 
develop a control strategy to reduce the risk of failed 
batches.
 
Table 5: Initial Risk Assessment of Drug Product Manufacturing Process of SLN 
Drug Product CQAs 
Process Steps 
High Pressure Homogenization Probe Sonication 
Particle Size High High 
% EE Low Low 
 
Table 6: Justification for Initial Risk Assessment of Drug Product Manufacturing Process of SLN 
Process Steps Drug Product CQAs Justification 
High Pressure 
Homogenization 
Particle Size 
Particle size of SLN decreases with increase in sonication time. 
Hence, risk was High. 
% EE Increase in HPH time doesn’t affect % EE, hence risk was low 
Probe Sonication 
Particle Size 
Probe sonication time is inversely proportional to particle size of 
SLN, hence risk was high. 
% EE 
Increase in probe sonication time has no significant effect on 
%EE, hence risk was low. 
 
Construction of Pseudo ternary Phase Diagram 
Phase diagram is needed for systemic study of 
microemulsion composition. From this, the extent of 
microemulsion region can be identified and its relation 
to other phases can be established. The pseudo-ternary 
phase diagrams were constructed by drop wise addition 
of double distilled water to homogenous liquid mixture 
of lipid, surfactant, and co-surfactant by water titration 
method. 
A ratio of surfactant over co-surfactant (Km) i.e. S/Co 
was chosen and the corresponding mixture (Smix) was 
made. At desired Km value (1:1, 2:1, and 3:1).Phase 
diagrams were constructed to define the extent of the 
microemulsion regions i.e. proportion in which the three 
/ four essential components must be mixed to form a 
transparent, clear, single phase, homogeneous and stable 
microemulsion.
Momin et al                                                      Journal of Drug Delivery & Therapeutics. 2017; 7(1):1-12 4 
© 2011-16, JDDT. All Rights Reserved                                            ISSN: 2250-1177                                                    CODEN (USA): JDDTAO 
 
Figure 1: Pseudo-ternary phase diagram of Lipid (GMS) / Smix (Tween 80 and Sodium taurocholate) / Water at 
Km= 1, 2 and 3. 
 
Formulation of Factorial Batches of SLN: 
The factorial batches of Gemcitabine Hydrochloride 
loaded SLNs were prepared by applying 3
2 
Factorial 
Design with factor X1(Glyceryl monostearate GMS), X2 
(Surfactant concentration: Tween 80: Sodium 
Taurocholate) as two independent variable at Three 
levels (-), (0) and (+). The two dependent responses 
were Y1 (Particle size) and Y2 (Entrapment Efficiency). 
The coded levels and the actual values of the variables 
used in this factorial design shown in Table No. 6. 
Accordingly, total nine formulations were designed and 
the compositions of different formulations and Formula 
of the Factorial batches of SLN have been depicted in 
Table No. 7. 
 
Table 7: 3
2 
Factorial Batches 
Factorial Batch Coded Form Actual Form 
Gemcitabine Hydrochloride X1 X2 GMS Tween 80 
SLN1 + + 1.4 1.4 
SLN2 0 + 1.0 1.4 
SLN3 - + 0.6 1.4 
SLN4 + 0 1.4 1.0 
SLN5 0 0 1.0 1.0 
SLN6 - 0 0.6 1.0 
SLN7 + - 1.4 0.6 
SLN8 0 - 1.0 0.6 
SLN9 - - 0.6 0.6 
 
Table 8: Formulation composition for the preparation of SLN 
Sr.No Formulation Drug (mg) Composition expressed as % W/W 
Surfactant : Co-Surf Lipid 
1 SLN1 5 1.4 1.4 
2 SLN2 5 1.4 1.0 
3 SLN3 5 1.4 0.6 
4 SLN4 5 1.0 1.4 
5 SLN5 5 1.0 1.0 
6 SLN6 5 1.0 0.6 
7 SLN7 5 0.6 1.4 
8 SLN8 5 0.6 1.0 
9 SLN9 5 0.6 0.6 
 
Preparation of Gemcitabine Hydrochloride loaded 
SLN by High shear homogenization (HSH) 
technique
6
: 
Gemcitabine Hydrochloride loaded batch of SLN was 
prepared by High shear homogenization method for the 
preparation of SLN formulation, in the concentration as 
that of factorial batch using GMS as solid lipid,  
Tween80: Sodium Taurocholate as surfactant : co-
surfactant. In this method, accurately weighed 5mg of 
Gemcitabine Hydrochloride was dissolved in distilled 
water and in a separate vessel GMS, Tween 80 and 
Sodium Taurocholate were added in to it and heated on a 
water bath at 60°C. Once the mixtures reached at 60°C, 
the solution of drug was added to the GMS and Tween 
80 mixture in a closed vessel under stirring at 3000 rpm 
using homogenizer. After adding, mixing was continued 
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for another 20 minutes to get micro particulate 
dispersion. After homogenization the dispersions were 
subjected to probe sonication for further reduction of 
particle size so as to get nano particulate dispersion. 
Finally the formulations were stored under refrigeration 
(2-8°C) until further use
6
. 
Evaluation of Gemcitabine Hydrochloride loaded 
SLN: 
Optical Microscopy of factorial batches of SLN:  
the prepared SLN dispersion of drugs was determined by 
using Motic Digital Microscope for Morphology, size 
and shape. The formulations was placed on the slide and 
observed under 100X magnification
7
. 
% Entrapment efficiency (%EE):  
The Gemcitabine Hydrochloride loaded SLN suspension 
was acidified to pH 1.2 after aggregation of the SLNs 
solution was immediately separated by centrifugation. 
Supernatant was withdrawn, filtered with syringe filter. 
1ml of filtrate was diluted to 10ml with distilled water 
and absorbance was measured at 268nm by UV 
spectrophotometer. The entrapment efficiency (EE %) 
was determined using the following equations
7
: 
 
Optimization of Factorial Batches of SLN: 
All the Factorial batches of SLN formulation were 
further optimized on the basis of evaluations and with 
the help of Design-Expert Software. 
Freeze Dried of Optimized SLN Batches: 
Free flowing SLN powder was prepared by freeze 
drying of optimized batch of SLN dispersion. Different 
parameters were applied in order to obtain free flowing 
SLN powder. Prior to freeze drying the SLN dispersion 
was mixed with trehalose (2.5% to 10%) which was 
used as cryoprotectant.  Freeze drying was carried out 
for 72 h with parameters. SLN obtained after drying 
process were in the form of powder. All lyophilized 
samples were therefore stored at 2-8 °C in refrigerator.  
Particle size analysis and polydispersity index (PI):  
Mean particle size and size distribution of optimized 
batch of SLN was determined by dynamic light 
scattering using Malveren zetasizer at room temperature. 
Before measurement, batches were diluted with filtered 
double distilled water until the appropriate concentration 
of particles was achieved to avoid multi-scattering. 
Zeta Potential: 
Charge on drug loaded droplet surface was determined 
using Malveren Zetasizer. Analysis time was kept for 
60s and average ZP, charge and mobility of optimized 
batch of SLN was determined. All measurements were 
done at 25°C 
Powder X-ray diffractometry:  
PXRD study reveals information about the 
crystallographic structure, chemical composition, and 
physical properties of materials. Freeze dried product of 
optimized Gemcitabine Hydrochloride loaded SLN 
batches of the same were irradiated with 
monochromatised CuKα radiation and analyzed between 
10 ° to 70 °(2θ). PXRD study was carried out by using 
X-ray Diffractometer. 
Differential Scanning Calorimetry: 
Thermograms of pure drug, freeze dried product of 
optimized batches of Gemcitabine Hydrochloride loaded 
SLN of the same were obtained using  DSC  equipped 
with an intracooler. Platinum crucible used with alpha 
alumina powder as reference to calibrate the DSC 
temperature and enthalpy scale. The powder samples 
was hermetically kept in the aluminium pan and heated 
at constant rate 10°C per min, over a temperature range 
of 35°C to 250°C. Inert atmosphere was maintained by 
purging nitrogen at the flow rate of 150mL/min. 
Scanning electron microscopy: 
The size, shape and morphology of prepared freeze dried 
optimized batch of Gemcitabine Hydrochloride loaded 
SLN were taken in SEM. Samples were coated with 
platinum using auto fine coater for 75 sec. at a 40mA 
operating current. Thickness of coating was less than 
25nm. The images were taken at different magnification 
and in the following operating conditions: acceleration 
voltage of 20 kV, working distance of 36mm, sample 
height in the range of 15 to18mm, spot size of 40 to 50 
and high vacuum mode. 
In vitro drug release studies: 
In vitro release of Gemcitabine Hydrochloride  loaded 
Optimized SLN5 batch was evaluated in PBS pH 7.4 for 
24 h using cellulose membrane dialysis bags  having 60 
ml/feet volume capacity, 2.5mm average flat width, 
16mm diameter; 12,000 g/mole molecular weight cut-
off. SLN dispersion was transferred to dialysis tubing 
and both ends were tightly sealed. The dialysis tube was 
placed in a beaker containing 100 ml of dissolution 
medium(PBS pH7.4) and magnetically stirred at 100 
rpm. After each sampling the dissolution media were 
completely replaced with 100ml of fresh media, to 
maintain sink conditions, defined as the volume of 
medium being at least three times higher than that 
necessary to obtain a saturated solution of drug
7
. 
Samples were withdrawn at predetermined time intervals 
of 1 h up to 24 h and analyzed spectrophotometrically 
using UV visible spectrophotometer at 268 nm.  
Accelerated stability studies: 
The accelerated stability studies were carried out 
according to International Conference on Harmonization 
(ICH) Q1A (R2) guide lines (FDA, 2003), with the 
optimized Gemcitabine Hydrochloride loaded SLN. 
Sealed vials of freshly prepared freeze-dried SLN 5 (3 
samples) were placed in stability chamber maintained at  
25°C ± 2°C & 60% RH ± 5%.The SLN dispersions 
subjected to stability test were analyzed over 3 month 
period for particle size, PDI of nanoparticles with 
sampling frequency of 1month
7
.  
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In-vitro anticancer activity
12-13
: 
Procedure: 
The SRB assay test was used to evaluate the cellular 
viability of so as to determine the cytotoxic effect of free 
and entrapped Gemcitabine Hydrochloride on human 
lung carcinoma cells A-549 (obtained from 
ACTREC,TATA Memorial Centre Khargar Mumbai). 
The cell viability was evaluated by determining The cell 
lines were grown in RPMI 1640 medium containing 
10% fetal bovine serum and 2 mM L-glutamine. For 
present screening experiment, cells were inoculated into 
96 well microtiter plates in 100 µL at plating densities as 
shown in the study details above, depending on the 
doubling time of individual cell lines. After cell 
inoculation, the microtiter plates were incubated at 37° 
C, 5 % CO2, 95 % air and 100 % relative humidity for 
24 h prior to addition of experimental drugs.  
Experimental drugs were initially solubilized in 
dimethyl sulfoxide at 100mg/ml and diluted to 1mg/ml 
using water and stored frozen prior to use. At the time of 
drug addition, an aliquote of frozen concentrate 
(1mg/ml) was thawed and diluted to 100 μg/ml, 200 
μg/ml, 400 μg/ml and 800 μg/ml with complete medium 
containing test article. Aliquots of 10 µl of these 
different drug dilutions were added to the appropriate 
microtiter wells already containing 90 µl of medium, 
resulting in the required final drug concentrations i.e.10 
μg/ml, 20 μg/ml, 40 μg/ml, 80 μg/ml.  
After compound addition, plates were incubated at 
standard conditions for 48 hours and assay was 
terminated by the addition of cold TCA. Cells were 
fixed in situ by the gentle addition of 50 µl of cold 30 % 
(w/v) TCA (final concentration, 10 % TCA) and 
incubated for 60 minutes at 4°C. The supernatant was 
discarded; the plates were washed five times with tap 
water and air dried. Sulforhodamine B (SRB) solution 
(50 µl) at 0.4 % (w/v) in 1 % acetic acid was added to 
each of the wells, and plates were incubated for 20 
minutes at room temperature. After staining, unbound 
dye was recovered and the residual dye was removed by 
washing five times with 1 % acetic acid. The plates were 
air dried. Bound stain was subsequently eluted with 10 
mMtrizma base, and the absorbance was read on an plate 
reader at a wavelength of 540 nm with 690 nm reference 
wavelength. Percent growth was calculated on a plate-
by-plate basis for test wells relative to control wells. 
Percent Growth was expressed as the ratio of average 
absorbance of the test well to the average absorbance of 
the control wells * 100.  
Using the six absorbance measurements [time zero (Tz), 
control growth (C), and test growth in the presence of 
drug at the four concentration levels (Ti)], the 
percentage growth was calculated at each of the drug 
concentration levels. Percentage growth inhibition was 
calculated as: [Ti/C] x 100 % 
RESULTS AND DISCUSSION: 
Determination of λmax of Gemcitabine Hydrochloride 
in PBS (PH 7.4):  
The absorbance maximum was found to be at 268 nm.  
Compatibility Studies: 
Compatibility studies shows no any significant changes 
were observed in the spectra as shown in figure No. 2
 
 
Figure 2: FTIR Overlay spectra of Gemcitabine Hydrochloride & Physical Mixture 
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Optical Microscopy of factorial batches of SLN: 
 
Figure 3: Droplet Size Determination of Gemcitabine Hydrochloride SLN Factorial Batches by Motic Image 
Plus 
Analysis of results indicates that the particle was 
spherical in shape and size range was 0.35µm to 
0.80µm. As the lipid load was increased particle size 
was also increased but surfactant concentration played 
important role in maintaining particle size in submicron 
range as shown in figure No. 3.  
% Entrapment efficiency (%EE): 
Table 9: % Entrapment efficiency of factorial 
batches of SLN 
Batch Code Entrapment efficiency (%) 
SLN1 39.16± 0.69 
SLN2 46.57± 0.11 
SLN3 57.93±0.47 
SLN4 48.8± 0.25 
SLN5 76.87± 0.41 
SLN6 59.45±1.29 
SLN7 68.41±1.29 
SLN8 62.14±1.29 
SLN9 66.70±1.29 
 
% Entrapment efficiency of batches under investigation 
was in the range of 39.16±0.69 to 76.87±0.41%, shown 
in Table No. 9. Batch SLN 5 showed highest 
entrapment efficiency 76.87±0.41% whereas, SLN1 
showed lowest % Entrapment efficiency 39.16±0.69 %. 
Optimization of the Factorial Batches of SLN: 
A 3
2 
randomized full factorial design was utilized in the 
present study. The different independent variables 
include: GMS (A), Tween80: Sodium taurocholate (B) 
concentration. The batches were evaluated and the effect 
of individual variable was studied according to the 
response surface methodology. The dependent response 
includes Particle Size (Y1) and Entrapment Efficiency 
(Y2). To describe the response surface curvature, the 
design was evaluated by quadratic model, which bears 
the following equations.  
Particle Size = 2.20 -0.30*A[1] +3.466E-017*A[2] -
0.50*B[1] – 0.067*B[2] ……..(1) 
The equation presents a positive effect of GMS (Factor 
A) concentration and a negative effect of Surfactant 
(Factor B) concentration on particle size, indicating an 
increase in particle size as the concentration of GMS 
increases and decrease in particle size as the 
concentration of Surfactant increases. The combined 
effect of X1 & X2 indicates significant effect on particle 
size. 
% EE = 82.05 +0.74*A[1] +2027*A[2] +2071*B [1] 
…………………………...….(2) 
The equation presents a positive effect of GMS (Factor 
A) and Surfactant (Factor B) concentration on %EE, 
indicating an increase in %EE as the concentration of 
GMS and concentration of Surfactant increases. The 
combined effect of A & B indicates significant effect on 
particle size. 
Response Surface Analysis: 
3- D response surface plots for variables Y1 (Particle 
size) and Y2 (%EE) are shown in Figures 4 and 5. 
The response surface plot indicates that for 0.35 µm 
Particle size, the concentrations of GMS and Tween80: 
STC are1gm and 1gm respectively. It shows that 
Particle size decreases as the concentration of Tween80: 
STC increases, and particle size increases with increase 
in the concentration of GMS. 
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Figure 4: Response Surface Plot (3D Surface Plot) showing Effect of Formulation Variables on Particle Size (Y1) 
of GEM loaded SLN 
 
Figure 5: Response Surface Plot (3D Surface Plot) showing Effect of Formulation Variables on % Entrapment 
Efficiency (Y2) of GEM loaded SLN 
 
The response surface plot indicates that for 61.7067% 
Entrapment Efficiency, concentrations of GMS and 
Tween80: STC are1gm and 1gm respectively. 
It shows that % Entrapment Efficiency increases as the 
concentration of GMS. 
Full Factorial design was used to develop design space 
in order to optimize and evaluate the effects of the CPPs 
(material attributes) on the CQAs, using the Design 
expert software. The factorial batches were evaluated 
and the effect of individual variable was studied 
according to the response surface methodology. 
The process was optimized for dependent variables Y1 
(Particle size) and Y2 (Entrapment Efficiency). Using 
the polynomial equations, the optimized formulation was 
obtained from the surface response counter plot. The 
optimized formula was obtained by targeting Y1 
between the range of 0.35 to 0.80 µm for Gemcitabine 
Hydrochloride respectively and, Y2 between the range 
39.16 to 76.87% for Gemcitabine Hydrochloride. The 
optimized batch obtained out of the 9 batches, results 
was determined and the results of optimized formula 
were compared with the predicted values in Table No. 
10 that indicates good relationship between experimental 
and predicted values confirming the practicability and 
validity of the model for both the Gemcitabine 
Hydrochloride loaded SLN. 
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Table 10: Comparison between the Experimented and Predicted Values for Most Probable Optimal Formulations 
Dependant 
Variables 
Optimized SLN Formulation of Gemcitabine HCl 
Experimental values Predicted values 
Particle Size 0.35 µm 0.39 µm 
% EE 76.87 % 61.70% 
 
The software design expert 9 and results suggested SLN 
5 as an optimized batch, hence the concentration of 
batch SLN 5 batch was selected for final formulation 
with 1gm of GMS, 1gm of Tween80: Sodium 
taurocholate and for Gemcitabine Hydrochloride loaded 
SLN.  
Particle size analysis and polydispersity index (PI): 
Figure No. 6 indicates that nanoparticles are of 168.6 
nm size. The mean particle size diameter/Z-average of 
Gemcitabine Hydrochloride loaded SLN was found to 
be126.1nm size respectively. PDI shows the particle size 
distribution. PDI of Gemcitabine Hydrochloride loaded 
SLN was obtained as 0.598 for optimized colloidal 
nanoparticle dispersion of SLN.  
 
 
Figure 6: Particle Size Distribution by Intensity of Optimized Batch of Gemcitabine Hydrochloride loaded SLN 
 
Zeta Potential: 
Zeta potential of optimized formulations of Gemcitabine 
Hydrochloride loaded SLN was found to be -28.9 mV 
respectively (Figure No. 7.) which indicated good 
stability 
% Entrapment efficiency (%EE) 
The % Entrapment Efficiency of optimized batch of 
Gemcitabine Hydrochloride loaded SLN was found to 
be 74.83% respectively. There was very less difference 
in % EE as compared to the SLN 5 factorial batch 
(76.87 respectively). 
 
 
Figure 7: Zeta Potential of Optimized Batch of Gemcitabine Hydrochloride loaded SLN 
 
Powder X-ray diffractometry: 
In PXRD studies, the diffractogram of a freeze dried 
optimized batch was analyzed to know any changes in 
crystallinity of drug and excipients in the batches. X-ray 
diffraction analysis was performed to determine whether 
the entrapped Gemcitabine Hydrochloride existed in the 
less crystalline state or the more amorphous state. Sharp 
peaks in X-ray diffraction spectra indicate a crystalline 
structure.  
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Figure 8: PXRD spectra of Freeze dried batch of Gemcitabine Hydrochloride loaded SLN 5 
 
Differential scanning Calorimetry: 
The DSC spectra of pure Gemcitabine Hydrochloride 
shows sharp endothermic peak at 286.0⁰C. The DSC of 
freeze dried optimized SLN batch shows shifting of 
endothermic peak at 278.41°C shows in figure No. 9. 
Scanning electron microscopy: 
SEM photographs of freeze dried SLN5 batch as shown 
in Figure No.10. at different magnification reveals that 
the particles are nearly spherical in shape with a smooth 
surface and particles are in nanometric range. 
 
Figure 9: DSC of Gemcitabine Hydrochloride (A) & 
freeze dried of optimized batch of Gemcitabine 
Hydrochloride loaded SLN (B).
 
 
Figure 10: SEM photograph of freeze dried optimized batch of Gemcitabine Hydrochloride loaded SLN product 
at different magnification. 
 
In vitro drug release studies: 
Significant variation in the release rate was observed in 
prepared optimized SLN batch. Results reveal initial 
burst release in first 2 h. for SLN5 batch, where nearly 
4-16 % of drug was released which may be due to drug 
adsorbed at the surface of nanoparticles or precipitated 
in the superficial lipid matrix. Drug release in later stage 
was continuous and slow indicating that the drug release 
rate was following diffusion from the rigid matrix 
structure. However, it was also observed that any change 
in concentration of surfactant and lipid load also altered 
the percentage release from all the formulations. 
Initial fast, later slow release of the Gemcitabine 
Hydrochloride loaded SLN 5 suggests drug enriched 
shell with core shell model. Method of preparation 
applied for preparing SLN is responsible for formation 
of drug enriched shell of SLN 5. During preparation 
partitioning of drug might have taken place into water 
phase at high temperature which upon cooling, lipid 
precipitated first, forming a practically drug free lipid 
core due to phase separation with drug rich lipid shell. 
The drug re-partitions into the remaining liquid-lipid 
phase and drug concentration in the outer shell 
increasing gradually. After 24hrs drug release was found 
to be 63.13% as shown in figure No. 11. 
Accelerated stability studies:  
The results reported in Table No.11 indicate small 
increase in particle size and PI of SLN in the dispersion. 
There was no physical change such as precipitation of 
lipid and color. Prepared dispersion of SLN5 was stable 
during accelerated stability study. 
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Figure 11: Average release of Gemcitabine from optimized SLN 5 batch 
In-vitro anticancer activity: 
Biological efficacy of Gemcitabine Hydrochloride 
entrapped in SLN5 was tested on human lung carcinoma 
cells (A-549) by using SRB assay. Empty SLN were 
used to evaluate possible toxic effect of the carrier on 
human lung carcinoma cells. After in incubation free 
Gemcitabine Hydrochloride elicited little cytotoxic 
effect at the investigated concentrations on lung 
carcinoma cells, which presents a viability of about 
15.3% to 27.0%. A significant improvement of 
anticancer activity with respect to the free drug was 
obtained by using Gemcitabine Hydrochloride loaded 
SLN. The SLN formulation showed a dose-dependent 
anticancer activity on human lung carcinoma cells. A 
significant difference was observed between free drug 
and SLN formulation at a concentration of 80μg/ml i.e. 
cell viability is 15.3 % & 18.1 % respectively after 24 h 
incubation. Lung carcinoma cells showed an 
improvement of efficacy of SLN formulation over the 
free drug. The improvement of Gemcitabine anticancer 
efficiency on lung carcinoma cells provided by SLN 
formulation suggests the protective and long circulation 
properties of it. 
 
Table 11: Change in particle size and PI of SLN in the dispersion during stability study 
Time of 
Sampling 
(month) 
Particle Size PI 
Zero time  After sampling 
(nm) 
Zero time After sampling (nm) 
1 126.1 152.6 0.598 0.612 
2 126.1 154.7 0.598 0.634 
3 126.1 155.8 0.598 0.623 
 
 
Figure 12: Positive Control Growth Activity on Human Lung Cancer Cell A-549 
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Figure 13: Dose-dependent anticancer activity of 
free drug, SLN formulations on   human lung 
carcinoma cells by SRB assay 
CONCLUSIONS: 
Incorporation of Gemcitabine Hydrochloride in SLN 
by QBD approach was successfully carried out with 
significant enhancement in drug entrapment, improved 
stability and achievement of extended release. 
Gemcitabine Hydrochloride loaded Solid lipid 
Nanoparticles were successfully formulated and 
evaluated to sustain the drug release by by passing the 
first pass metabolism. Gemcitabine Hydrochloride 
loaded SLN in the treatment of Human Lung Cancer 
for prolonged release of action as well as reduced the 
dose of the drug was achieved. Moreover in vitro 
anticancer activity has showed remarkable 
improvement. 
ACKNOWLEDGMENTS: 
Author is Thankful to Renuka raw pharma Mumbai for 
Supplying gift sample of  Gemcitabine Hydrochloride, 
and also thankful to ACTREC Mumbai for helping in 
Cell line study.  
CONFLICTS OF INTEREST: 
No conflicts of interest. Authors alone are responsible 
for the content and writing of the paper. 
REFERENCES: 
1. Mitra S, Mitra AN. Nanoparticulate carriers in drug 
delivery and targeting. PINSA B68 No. 4, 2002; pp 349-
360.  
2. Abratt RP. Gemcitabine Hydrochloride: Combination of 
activity and tolerability. Anticancer Drugs, 1995; 6:63-64. 
3. Manjunath K, Reddy JS, Venkateswarlu V., Solid lipid 
nanoparticles as drug delivery systems, Methods Find. Exp. 
Clin. Pharmacol. 2005; 27:127-144. 
4. Müller RH, Mehnert W, Lucks JS, Schwarz C, Zur Mühlen 
A, Weyhers H, Freitas C, Rühl D, Solid lipid nanoparticles 
(SLN) - An alternative colloidal carrier system for 
controlled drug delivery, Eur. J. Pharm. 1995; 41:62-69.  
5. Gohla S, Rainer H, MuÈller, Karsten MaÈder, Solid lipid 
nanoparticles (SLN) for controlled drug delivery - A review 
of the state of art. Eur. J. Pharm. Biopharm. 2000; 50:161-
177.   
6. Lawrence TS. Radiation sensitizers and targeted therapies, 
oncology. 2003; 17:23-28. 
7. Mokashi AS, Solid lipid nanoparticles of gemcitabine 
hydrochloride. bentham science publishers 2012; 2:0000-
0000. 
8. Siekmann B, Westesen K. Investigations on solid lipid 
nanoparticles prepared by precipitation in o/w emulsions. 
Eur. J. Pharm. Biopharm.(1996; 43:104-109.  
9. Reddy LH. Couvreur, P.Novel Approaches to deliver 
gemticabine to cancers. Curr.Pharm. Des., 2008; 14:1124-
1137. 
10. Lionberger RA, Lee LS, Lee L, Raw A ,Yu LX, Quality by 
design: Concepts for ANDAs, The AAPS Journal, 2008; 
10:268–276. 
11. Nadpara NP, Quality By Design (QBD): A complete 
Review. Int.J.pharm.sci.Rev.Res. 2012; 17(2):04, 20-28. 
12. Skehn P, Storeng R, Scudiero A, Monks J, McMohan D, 
Vistica D, Jonathan TW, Bokesch H, Kenney S, Boyd M R. 
New colorimetric cytotoxicity assay for anticancer drug 
screening J. Natl. Cancer Inst. 1990; 82:1107.  
13. Vichai V, Kanyawim K. Sulforhodamine B colorimetric 
assay for cytotoxicity screening Nature Protocols. 2006; 
1:1112-1116. 
 
